Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuron Ltd ADR (NQ: IMRN )

1.900 -0.050 (-2.56%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immuron Ltd ADR

< Previous 1 2 Next >
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
From Immuron Limited
Via GlobeNewswire
Immuron Travelan® continued strong sales growth
From Immuron Limited
Via GlobeNewswire
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
From Immuron Limited
Via GlobeNewswire
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
From Immuron Limited
Via GlobeNewswire
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
From Immuron Limited
Via GlobeNewswire
Immuron announces record Travelan® sales globally, Australia and USA
From Immuron Limited
Via GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
From Immuron Limited
Via GlobeNewswire
Immuron Board Changes
From Immuron Limited
Via GlobeNewswire
Immuron CEO Steven Lydeamore to present at Peak Sky High
From Immuron Limited
Via GlobeNewswire
Immuron Limited to Present at the Emerging Growth Conference
From Immuron Limited
Via GlobeNewswire
Immuron Director Resignation
From Immuron Limited
Via GlobeNewswire
Immuron to host Live Virtual Event
From Immuron Limited
Via GlobeNewswire
Immuron Travelan® sales continued strong growth
From Immuron Limited
Via GlobeNewswire
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
From Immuron Limited
Via GlobeNewswire
Immuron Presentation Australian Biologics Festival 2024
From Immuron Limited
Via GlobeNewswire
Immuron achieves record Travelan® sales
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
From Immuron Limited
Via GlobeNewswire
Immuron achieves record half yearly Travelan® sales
From Immuron Limited
Via GlobeNewswire
Immuron Clinical Trials Update
From Immuron Limited
Via GlobeNewswire
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
From Immuron Limited
Via GlobeNewswire
Immuron CEO Steven Lydeamore Investor Webinar Presentation
From Immuron Limited
Via GlobeNewswire
Immuron CEO Steven Lydeamore presented at AusBioInvest
From Immuron Limited
Via GlobeNewswire
Immuron Announces Travelan® Clinical Study Cohort 2 commences
From Immuron Limited
Via GlobeNewswire
Immuron achieves record quarterly Travelan® sales
From Immuron Limited
Via GlobeNewswire
Immuron hails record monthly sales of Travelan
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®.... 
Via TheNewswire.com
Immuron achieves record monthly Travelan® sales
From Immuron Limited
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.